ESPE Abstracts

Introduction: The retrospective/blind glucose monitoring (bCGM) system or glucose sensors commonly used for type 1 diabetes management. The approach to hyperglycemic and hypoglycemic states is an urgent and essential issue in terms of diagnosis/treatment. Many tests are performed for the diagnostic process. We aimed to evaluate the effectiveness of bCGM (iPro™2 system) in the follow-up and treatment of patients to our clinics with hypoglycemia/hyperglycemia.

Methods: The data from 69 cases with the iPro™2 system were analyzed retrospectively. The cases were divided into two groups according to the indications for sensor application (hypoglycemic and hyperglycemic group). Group characteristics and sensor data were analyzed in detail.

Results: 59.4% (n=41) of the cases were followed up due to hyperglycemia. Of the cases in this group, 21 had type 1 diabetes mellitus (T1DM), and 1 had neonatal diabetes. Five cases who did not meet the diagnostic criteria for diabetes at admission and planned to follow up were diagnosed with diabetes after sensor measurements. Three patients with Cystic fibrosis (CF) and one with thalassemia major were followed up with the sensor. Ten cases referred with the suspected hyperglycemia were normal. Treatment modification in the patient with diabetes was guided by the glucose variability and pattern in the sensor report. The sensor was a valuable tool in cases admitted in the prediabetes stage. Impaired glucose metabolism was detected in patients with CF and thalassemia major. So, an appropriate nutrition plan was made, and medical treatment was modulated. The cases with normal sensor data were excluded from follow-up, and there was no unnecessary further investigation. Conclusion: This study shows that bCGM systems can be a valuable tool for diagnosing and management of hyperglycemic and hypoglycemic states.